Spondyloarthritis News and Research

RSS

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

Novartis announced today late-breaking two year results for Cosentyx® (secukinumab) showing up to 80% of patients with ankylosing spondylitis (AS) had no radiographic progression in the spine on x-ray assessment. This is the first time that data on structural spinal progression in AS have been presented for an interleukin-17A (IL-17A) inhibitor.

9 Nov 2015

ACR releases new recommendations for treatment of AS and non-radiographic axial SpA

The American College of Rheumatology has released new recommendations for the treatment of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (SpA).

26 Sep 2015

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA).

26 Jun 2015

Crescendo Bioscience to present new data on Vectra DA at ACR Annual Meeting

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced that new data on Vectra DA will be featured at the 2014 American College of Rheumatology Annual Meeting, Nov. 15-19, 2014, in Boston, Massachusetts.

12 Nov 2014

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Inflammatory hindfoot arthrodesis outcomes compared

Choice of arthrodesis for patients with rheumatoid arthritis or spondyloarthritis hindfoot disease should be guided by the extent of damage present, research indicates.

6 Sep 2012

MRI lesions match site of recent-onset inflammatory back pain

Patients with recent inflammatory back pain who undergo examination with magnetic resonance imaging typically show inflammation at the site of their pain, a study confirms.

3 Sep 2012

Study identifies 5 biomarkers that may predict progression of spinal damage in AS patients

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, has identified five biomarkers that may predict the progression of structural damage in the spine of patients with Ankylosing Spondylitis (AS) who are already at high risk of disease progression.

7 Jun 2012

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.

6 Jun 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the Phase 3 ABILITY-1 study of HUMIRA (adalimumab) in patients with active non-radiographic axial spondyloarthritis.

7 Nov 2011

Potential predictors of spinal damage progression in people with spondyloarthritis

The presence of syndesmophytes (bony growths in the spine), acute phase reactants (proteins that are released into the blood in response to inflammation), and smoking status can all serve as predictors for the progression of structural damage in the spine in people with spondyloarthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott scientists and independent researchers will highlight the latest research findings on HUMIRA (adalimumab) at this year's American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5-9 in Chicago.

3 Nov 2011

UTHealth inaugurates new center for autoimmune and inflammatory diseases research

The University of Texas Health Science at Houston (UTHealth) announced the opening of a center devoted to researching and treating diseases associated with malfunctioning immune systems.

2 Sep 2011

Big news for ankylosing spondylitis sufferers

In a medical breakthrough, researchers from the University of Queensland have found that there is a possible genetic link in a specific painful form of arthritis, which fuses bones in the spine and pelvis.

12 Jul 2011

New genetic clues about ankylosing spondylitis

A study involving over 5,000 people living with the joint disorder ankylosing spondylitis has identified a series of genetic variants associated with increased susceptibility to the condition as well as providing new clues to how the condition may be treated in the future.

11 Jul 2011

Spondyloarthritis News and Research

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

ACR releases new recommendations for treatment of AS and non-radiographic axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Crescendo Bioscience to present new data on Vectra DA at ACR Annual Meeting

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Inflammatory hindfoot arthrodesis outcomes compared

MRI lesions match site of recent-onset inflammatory back pain

Study identifies 5 biomarkers that may predict progression of spinal damage in AS patients

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott announces results from HUMIRA Phase 3 study on axSpA

Potential predictors of spinal damage progression in people with spondyloarthritis

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

UTHealth inaugurates new center for autoimmune and inflammatory diseases research

Big news for ankylosing spondylitis sufferers

New genetic clues about ankylosing spondylitis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News